The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study

Overview of attention for article published in Frontiers in Pharmacology, August 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 5,739 followers.

New Research: The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study https://t.co/9MT2PZiaN6 #pharmacology

26 Aug 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.